Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting

INTRODUCTION: Long-acting somatostatin analogues such as lanreotide autogel (LAN) and octreotide long-acting release (OCT) are recommended as first-line treatment for patients with neuroendocrine tumors (NETs). However, only few real-world studies have compared the two medications. This retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrow, Brooke, Fagnani, Francis, Nevoret, Camille, Truong-Thanh, Xuan-Mai, de Zélicourt, Marie, de Mestier, Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989892/
https://www.ncbi.nlm.nih.gov/pubmed/35190997
http://dx.doi.org/10.1007/s12325-022-02060-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989892/
https://www.ncbi.nlm.nih.gov/pubmed/35190997
http://dx.doi.org/10.1007/s12325-022-02060-1

Ejemplares similares